Gene therapy for fanconi anemia: One step closer to the clinic

Human Gene Therapy

Volumn 23, Issue 2, 2012, Pages 141-144

  Tolar, Jakub ^a   Becker, Pamela S ^b   Clapp, D Wade ^c   Hanenberg, Helmut ^c,d   De Heredia, Cristina Díaz ^e   Kiem, Hans Peter ^f   Navarro, Susana ^g,h   Qasba, Pankaj ⁱ   Rio, Paula ^g,h   Schmidt, Manfred ^j   Sevilla, Julián ^k   Verhoeyen, Els ^l   Thrasher, Adrian J ^m,n   Bueren, Juan ^g,h  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Fred Hutchinson Cancer Research Center   (United States)

^g CIEMAT   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^k HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^l UNIVERSITÉ LYON 1   (France)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ Great Ormond Street Hospital NHS Trust ^*  (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYCLOPHOSPHAMIDE; FANCONI ANEMIA GROUP A PROTEIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; PLERIXAFOR;

BONE MARROW DEPRESSION; CD34 SELECTION; DNA DAMAGE; DNA MODIFICATION; ENDOCRINE DISEASE; FANCONI ANEMIA; GENE THERAPY; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IONIZING RADIATION; LEUKEMIA; METASTASIS; MYELODYSPLASTIC SYNDROME; NOTE; VESICULAR STOMATITIS VIRUS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DNA DAMAGE; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; GENETIC THERAPY; HUMANS;

EID: 84856920873     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.237     Document Type: Note

References (31)

1. Becker, P.S., Taylor, J.A., Trobridge, G.D., et al. (2010). Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. Gene Ther. 17, 1244-1252.
2. Churchill, W., and Langworth, R.M. (2008). Churchill by Himself: The Definitive Collection of Quotations. PublicAffairs, New York, p. 8.
3. Croop, J.M., Cooper, R., Fernandez, C., et al. (2001). Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. Blood 98, 2917-2921.
4. D'Andrea, A.D. (2010). Susceptibility pathways in Fanconi's anemia and breast cancer. N. Engl. J. Med. 362, 1909-1919.
5. Dipersio, J.F., Stadtmauer, E.A., Nademanee, A., et al. (2009). Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113, 5720-5726.
6. Evans, M. (2011). Discovering pluripotency: 30 years of mouse embryonic stem cells. Nat. Rev. Mol. Cell. Biol. 12, 680-686.
7. Fischer, A., Hacein-Bey-Abina, S., and Cavazzana-Calvo, M. (2010). 20 years of gene therapy for SCID. Nat. Immunol. 11, 457-460.
8. Frecha, C., Costa, C., Negre, D., et al. (2011). A novel lentivector targets gene transfer into hHSC in marrow from patients with BM-failure-syndrome and in vivo in humanized mice. Blood [Epub ahead of print]; DOI: 10.1182/blood-2011-04-346619.
9. Galimi, F., Noll, M., Kanazawa, Y., et al. (2002). Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood 100, 2732-2736.
10. Gonzalez-Murillo, A., Lozano, M.L., Alvarez, L., et al. (2010). Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. Hum. Gene Ther. 21, 623-630.
11. Gregory, J.J., Jr., Wagner, J.E., Verlander, P.C., et al. (2001). Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 98, 2532-2537. (Pubitemid 32209516)
12. Gross, M., Hanenberg, H., Lobitz, S., et al. (2002). Reverse mosaicism in Fanconi anemia: Natural gene therapy via molecular self-correction. Cytogenet. Genome Res. 98, 126-135. (Pubitemid 37465006)
13. in 't Anker, P.S., Noort, W.A., Kruisselbrink, A.B., et al. (2003). Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp. Hematol. 31, 881-889. (Pubitemid 37211372)
14. Jacome, A., Navarro, S., Rio, P., et al. (2009). Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol. Ther. 17, 1083-1092.
15. Kelly, P.F., Radtke, S., Kalle, C., et al. (2007). Stem cell collection and gene transfer in fanconi anemia. Mol. Ther. 15, 211-219. (Pubitemid 46043667)
16. Lee, S.T., Maeng, H., Chwae, Y.J., et al. (2008). Effect of mesenchymal stem cell transplantation on the engraftment of human hematopoietic stem cells and leukemic cells in mice model. Int. J. Hematol 87, 327-337.
17. Lo Ten Foe, J.R., Kwee, M.L., Rooimans, M.A., et al. (1997). Somatic mosaicism in Fanconi anemia: Molecular basis and clinical significance. Eur. J. Hum. Genet. 5, 137-148. (Pubitemid 27356701)
18. Macmillan, M.L., and Wagner, J.E. (2010). Haematopoietic cell transplantation for Fanconi anaemia: When and how? Br. J. Haematol. 149, 14-21.
19. Mankad, A., Taniguchi, T., Cox, B., et al. (2006). Natural gene therapy in monozygotic twins with Fanconi anemia. Blood 107, 3084-3090.
20. Muller, L.U., Milsom, M.D., Kim, M.O., et al. (2008). Rapid lentiviral transduction preserves the engraftment potential of Fanca-/-hematopoietic stem cells. Mol. Ther. 16, 1154-1160. (Pubitemid 351737082)
21. Naldini, L. (2011). Ex vivo gene transfer and correction for cellbased therapies. Nat. Rev. Genet. 12, 301-315.
22. Pulliam, A.C., Hobson, M.J., Ciccone, S.L., et al. (2008). AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice. Exp. Hematol. 36, 1084-1090.
23. Sevilla, J. (2012). Priming of hematopoietic progenitor cells by plerixafor plus filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment. Bone Marrow Transpl. (in press).
24. Shenoy, P.J. (2011). Plerixafor is highly effective for the mobilization of autologous PBSC for transplant in children failing to mobilize by conventional means: International experience with 40 children from 19 centers. Blood 2011, 53rd ASH Meeting.
25. Sheridan, C. (2011). Gene therapy finds its niche. Nat. Biotechnol. 29, 121-128.
26. Svahn, J., and Dufour, C. (2011). Fanconi anemia: Learning from children. Pediatr. Rep. (3 Suppl. 2), e8.
27. Thakar, M.S., Kurre, P., Storb, R., et al. (2011). Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 46, 539-544.
28. Tolar, J., Adair, J.E., Antoniou, M., et al. (2011). Stem cell gene therapy for Fanconi anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. Mol. Ther. 19, 1193-1198.
29. van der Loo, J.C., Hanenberg, H., Cooper, R.J., et al. (1998). Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells. Blood 92, 2556-2570. (Pubitemid 28453001)
30. Waisfisz, Q., Morgan, N.V., Savino, M., et al. (1999). Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat. Genet. 22, 379-383. (Pubitemid 29369531)
31. Watts, K.L., Delaney, C., Humphries, R.K., et al. (2010). Combination of HOXB4 and Delta-1 ligand improves expansion of cord blood cells. Blood 116, 5859-5866.